Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · IEX Real-Time Price · USD
25.40
+0.92 (3.76%)
At close: May 8, 2024, 4:00 PM
25.20
-0.20 (-0.79%)
After-hours: May 8, 2024, 7:58 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 352 employees on December 31, 2023. The number of employees increased by 53 or 17.73% compared to the previous year.
Employees
352
Change (1Y)
53
Growth (1Y)
17.73%
Revenue / Employee
$1,487,298
Profits / Employee
$332,912
Market Cap
2.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 352 | 53 | 17.73% |
Dec 31, 2022 | 299 | 61 | 25.63% |
Dec 31, 2021 | 238 | 2 | 0.85% |
Dec 31, 2020 | 236 | 30 | 14.56% |
Dec 31, 2019 | 206 | 40 | 24.10% |
Dec 31, 2018 | 166 | 30 | 22.06% |
Dec 31, 2017 | 136 | 33 | 32.04% |
Dec 31, 2016 | 103 | 7 | 7.29% |
Dec 31, 2015 | 96 | 25 | 35.21% |
Dec 31, 2014 | 71 | 7 | 10.94% |
Dec 31, 2013 | 64 | 8 | 14.29% |
Dec 31, 2012 | 56 | 20 | 55.56% |
Dec 31, 2011 | 36 | 1 | 2.86% |
Dec 31, 2010 | 35 | 8 | 29.63% |
Dec 31, 2009 | 27 | -4 | -12.90% |
Dec 31, 2008 | 31 | 10 | 47.62% |
Dec 31, 2007 | 21 | 1 | 5.00% |
Dec 31, 2006 | 20 | 1 | 5.26% |
Dec 31, 2005 | 19 | -1 | -5.00% |
Dec 31, 2004 | 20 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Bausch Health Companies | 20,270 |
ICU Medical | 14,000 |
LifeStance Health Group | 9,325 |
Neogen | 2,640 |
Inari Medical | 1,300 |
PTC Therapeutics | 995 |
Twist Bioscience | 919 |
MorphoSys AG | 524 |
CORT News
- 1 day ago - Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 7 days ago - Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 5 weeks ago - Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome - GlobeNewsWire
- 2 months ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial - GlobeNewsWire
- 3 months ago - Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 4 months ago - Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA) - Benzinga